SLBT (SL Science Holding) 10-Year RORE % : 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLBT SL Science Holding Ltd SLBT
12 GF Score
Price $3.29
! 3 Warning Signs
View Full Analysis

What is SL Science Holding 10-Year RORE %?

SL Science Holding SLBT +24.39% 12 10-Year RORE % is 0.00 as of Dec. 2025. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 613 Biotechnology companies, SL Science Holding ranks worse than 163131.97% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. SL Science Holding does not have enough data to calculate 10-Year RORE %.


SL Science Holding  (NAS:SLBT) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


SL Science Holding 10-Year RORE % Related Terms


SL Science Holding 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for SL Science Holding's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SL Science Holding 10-Year RORE % Chart

SL Science Holding Annual Data
Trend Dec23 Dec24 Dec25
10-Year RORE %
0.00 0.00 0.00

SL Science Holding Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
10-Year RORE % 0.00 0.00 0.00 0.00 0.00

SLBT vs DMRA, BCAX, TYRA: 10-Year RORE % Comparison

For the Biotechnology subindustry, SL Science Holding's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SL Science Holding 10-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SL Science Holding's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where SL Science Holding's 10-Year RORE % falls into.


SLBT
12GF Score
SL Science Holding Ltd SLBT
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SL Science Holding 10-Year RORE % Calculation

SL Science Holding's 10-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of 0.00 mean?
SL Science Holding (SLBT) has a 10-Year RORE % of 0.00 as of Dec. 2025. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on SL Science Holding and its competitors. According to the industry distribution chart, SL Science Holding ranks #999999 out of 613 companies in the Biotechnology industry.
Is SL Science Holding's 10-Year RORE % too high?
SL Science Holding's current 10-Year RORE % is 0.00. Based on the distribution chart, SL Science Holding ranks #999999 out of 613 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's 10-Year RORE % compare to DMRA and BCAX?
According to the Biotechnology industry distribution chart, SL Science Holding ranks #999999 out of 613 companies for 10-Year RORE %. This places SL Science Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Biotechnology company?
A good 10-Year RORE % depends on the Biotechnology industry context. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on SL Science Holding and its competitors. SL Science Holding's current 10-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current 10-Year RORE % of 0.00. The current 10-Year RORE % is 0.00. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For SL Science Holding (SLBT), the current 10-Year RORE % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SL Science Holding Business Description

Address No. 479 Chongyang Road, 11th Floor, Nangang District, Taipei, TWN, 115010
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score

Get the complete analysis for SLBT

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price